Results 141 to 150 of about 84,970 (256)

Mimickers of Amyotrophic Lateral Sclerosis

open access: yesAnnals of Indian Academy of Neurology, 2019
Ayush Dubey, Shubham Dubey
openaire   +3 more sources

Reachable Workspace as a Clinical Outcome for Upper Extremity Function: A Narrative Review

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Motion sensing technology can be utilized to capture detailed upper extremity (UE) motion to reconstruct an individual's three‐dimensional (3D) reachable workspace (RWS). The RWS can be quantified as relative surface area (RSA), providing an innovative surrogate measure to assess UE mobility and function.
Jay J. Han   +3 more
wiley   +1 more source

Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis. [PDF]

open access: yesInt J Mol Sci
Katz M   +6 more
europepmc   +1 more source

The Emotional Experiences of Healthcare Professionals Working in Amyotrophic Lateral Sclerosis: A Systematic Review

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Healthcare professionals (HCPs) working with people living with amyotrophic lateral sclerosis (ALS) are often exposed to emotive circumstances including end of life care, trauma, loss, and death. Existing reviews have explored the emotional experiences of people living with ALS and their carers but have largely ignored healthcare staff and the
Young Chan   +7 more
wiley   +1 more source

Plasma isomiRs as Candidate Biomarkers for Amyotrophic Lateral Sclerosis. [PDF]

open access: yesNeurol Genet
Magee RG   +6 more
europepmc   +1 more source

Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Tofersen is a gene‐targeted therapy for individuals with superoxide dismutase 1 (SOD1) (+) amyotrophic lateral sclerosis (ALS). Prior to U.S. Food and Drug Administration (FDA) approval, tofersen was made available through expanded access protocol.
Alison Wheeler   +30 more
wiley   +1 more source

Excitotoxicity in amyotrophic lateral sclerosis: a key pathogenic mechanism. [PDF]

open access: yesBrain Commun
Silva-Hucha S   +5 more
europepmc   +1 more source

At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Respiratory weakness, typically monitored as vital capacity (VC), is a central feature of amyotrophic lateral sclerosis (ALS). VC is increasingly measured remotely in participants' homes, although in‐clinic assessment remains the standard.
Eric A. Macklin   +269 more
wiley   +1 more source

No Evidence for an Association Between DIP2B Repeat Expansion and Neurological Disease

open access: yes
Movement Disorders, EarlyView.
Chia‐Ying Ko   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy